NanoSyrinx

NanoSyrinx is a discovery-stage biotechnology company developing a platform for targeted intracellular delivery of protein and peptide therapeutics.

Based on naturally occurring bacterial nanomachines, the company's technology is engineered to deliver biological payloads directly to the cytosol of targeted cells without viral vectors.

The platform is designed to address the intracellular bioavailability problem that limits the therapeutic potential of most biologic drugs, with applications spanning gene editing, cell therapy and undruggable oncology targets.